Financing of Gene Therapies-BIO
Challenge
Gene therapy is becoming increasingly important in treating rare diseases. As technology advances, adoption of and access to gene therapies requires understanding of their potential benefits as well as their risks, by all stakeholders, including patients.
Moreover, the elevated costs often linked to gene therapies can impede patient access to treatment. Consequently, drug manufacturers must employ strategic approaches to ensure effective market access while maintaining treatment affordability.
Our client sought to better understand the global environment regarding access and reimbursement for these and future therapies by convening a conference session at BIO International.
Our Solution
Conducted in-depth research to better understand the present gene therapy landscape as it applies to determining value, pricing and financing, research incentives, access, and clinical development.
Collaborated with the client, medical experts, and patient leaders from NORD, NICE, and IAPO to design, develop, and deliver a panel session on the financing of gene therapies at the BIO International Industry Conference in 2018.
Collaborated with medical experts and Rare Disease International to design, develop, and deliver a Gene Therapy Patient Education survey and session at the IAPO 8th Global Patients’ Congress in 2018.
Benefits to the Client
Comprehensive Gene Therapy Landscape Understanding: Attained valuable insights into the current and evolving landscape of gene therapy pricing, reimbursement, and access.
Empowered Research and Development Decisions: Equipped with the capability to make informed decisions regarding rare disease and gene therapy research and development programs.
Enhanced Patient Education and Awareness: Improved patient education and awareness of gene therapy.